You are here: Industry Insights > therapeutics

News List

Evotec & Indivumed Enter Research Collaboration ontractpharma
April 15, 2019
To discover and develop first-in-class therapeutics for the treatment of colorectal cancer.
Boehringer Ingelheim enhances oncology R&D with novel MacroDel delivery technology via acquisition of ICD Therapeutics worldpharmanews
April 10, 2019
Boehringer Ingelheim enhances oncology R&D with novel MacroDel delivery technology via acquisition of ICD Therapeutics...
Novel treatments offer new hope for patients with autoimmune disease worldpharmanews
March 06, 2019
Autoimmune diseases, including type 1 diabetes and multiple sclerosis, arise when the body's immune cells attack itself.
Knight Therapeutics invests up to $125m in Latin America-focused Moksha8 pharmaceutical-technology
February 20, 2019
Canada-based Knight Therapeutics has announced it has closed a strategic financing agreement of up to $125m with US-headquartered Moksha8....
Goodwin Bio, Radimmune Enter Oncology Pact contractpharma
November 19, 2018
Radimmune Therapeutics has selected Goodwin Biotechnology to develop a process and manufacture it's lead therapeutic
Akebia Therapeutics Sends Letter to Shareholders firstwordpharma
November 14, 2018
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (Nasdaq: AKBA) mailed a letter to Akebia shareholders in connection with the special meeting
Protagonist Therapeutics Announces Completion of Phase 1 Trial of PTG-200 americanpharmaceuticalreview
November 07, 2018
Protagonist Therapeutics Announces Completion of Phase 1 Trial of PTG-200
ProQR licenses Ionis’ RNA drug for inherited blindness fiercebiotech
November 02, 2018
ProQR is licensing an RNA medicine from Ionis Pharmaceuticals for the treatment of retinitis pigmentosa, a form of rare, inherited blindness. The plan is to start a phase 1/2 trial of...
LogicBio Announces Closing of Initial Public Offering firstwordpharma
October 25, 2018
LogicBio Announces Closing of Initial Public Offering
Protagonist Therapeutics Announces Fast Track Designation Granted by U.S. FDA to Hepcidin Mimetic PTG-300 pharmafocusasia
September 29, 2018
Protagonist Therapeutics, Inc today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to therapeutic candidate PTG-300 for the treatment of chronic anemia due to ineffective erythropoiesis in patients with beta-

Previous page 1 2 3 4 5 Next page